AstraZeneca Says Study in Liver Cancer Meets Objective
October 15 2021 - 8:05AM
Dow Jones News
By Michael Dabaie
AstraZeneca said results from its Himalaya Phase III trial
showed a single dose of tremelimumab added to Imfinzi significantly
improved overall survival in liver cancer.
The trial met the primary objective of overall survival with a
single priming dose of tremelimumab plus Imfinzi every four weeks
versus sorafenib for patients with unresectable hepatocellular
carcinoma, or HCC, the company said. Imfinzi monotherapy met the
overall survival endpoint of non-inferiority versus sorafenib,
AstraZeneca said.
Imfinzi and tremelimumab were granted orphan drug designations
in the U.S. for the treatment of HCC in 2020. Tremelimumab was also
granted orphan designation in the European Union in HCC in
2020.
Write to Michael Dabaie at michael.dabaie@wsj.com
(END) Dow Jones Newswires
October 15, 2021 07:50 ET (11:50 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
Astrazeneca (LSE:AZN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Astrazeneca (LSE:AZN)
Historical Stock Chart
From Sep 2023 to Sep 2024